{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:35:44Z","timestamp":1787639744774,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ard.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T04:12:46Z","timestamp":1766635966000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0547-6695","authenticated-orcid":false,"given":"L\u00e9a","family":"Perrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinson","family":"Gravier Dumonceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.11.010_bib0001","doi-asserted-by":"crossref","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 377(9783):2127-37.","DOI":"10.1016\/S0140-6736(11)60071-8"},{"issue":"12","key":"10.1016\/j.ard.2025.11.010_bib0002","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.11.010_bib0003","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0004","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.11.010_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10163","key":"10.1016\/j.ard.2025.11.010_bib0006","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.010_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.11.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003455","article-title":"Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry","volume":"9","author":"Ciurea","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.190008","article-title":"Placebo response in rheumatoid arthritis clinical trials","volume":"47","author":"Bechman","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.11.010_bib0011","article-title":"Global recruiting patterns and placebo response rates in clinical trials of psoriatic arthritis and Plaque Psoriasis","author":"Kerschbaumer","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.ard.2025.11.010_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s004150050560","article-title":"Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos","volume":"247","author":"De Craen","year":"2000","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.010_bib0014","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2025.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF\u03b1 treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.11.010_bib0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"10.1016\/j.ard.2025.11.010_bib0018","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"issue":"9313","key":"10.1016\/j.ard.2025.11.010_bib0019","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ard.2025.11.010_bib0020","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0021","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ard.2025.11.010_bib0022","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.010_bib0023","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.11.010_bib0024","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2025.11.010_bib0025","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0026","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.010_bib0027","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0028","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","article-title":"Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study","volume":"16","author":"Dougados","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.11.010_bib0029","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.010_bib0032","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.010_bib0033","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0034","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.11.010_bib0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.11.010_bib0036","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.010_bib0037","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"7","key":"10.1016\/j.ard.2025.11.010_bib0038","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two\u2013week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.010_bib0039","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"issue":"10217","key":"10.1016\/j.ard.2025.11.010_bib0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ard.2025.11.010_bib0041","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III China-centric study, MEASURE 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0042","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12891-021-04089-9","article-title":"Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials","volume":"22","author":"Park","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.ard.2025.11.010_bib0043","first-page":"114","article-title":"Placebo effects in neurological diseases","volume":"3","author":"Dumitriu","year":"2010","journal-title":"J Med Life"},{"issue":"8","key":"10.1016\/j.ard.2025.11.010_bib0044","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0895-4356(00)00206-7","article-title":"Stason WB. Do medical devices have enhanced placebo effects?","volume":"53","author":"Kaptchuk","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ard.2025.11.010_bib0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13075-015-0897-6","article-title":"Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients\u2013baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice","volume":"17","author":"Wallman","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.11.010_bib0046","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1016\/S2665-9913(25)00108-0","article-title":"The imaging crisis in axial spondyloarthritis","volume":"7","author":"Diekhoff","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.010_bib0047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-6-25","article-title":"The fading of reported effectiveness. A meta-analysis of randomised controlled trials","volume":"6","author":"Gehr","year":"2006","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.010_bib0048","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-8703(96)90465-2","article-title":"The placebo effect in cardiovascular disease","volume":"132","author":"Bienenfeld","year":"1996","journal-title":"Am Heart J"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:27:18Z","timestamp":1786192038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0003496725045364"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.010","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the placebo and treatment effect overtime in randomised clinical trials evaluating the efficacy of biologics in axial spondyloarthritis: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}